A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer

Siddhartha Yadav; Karthik V. Giridhar; Jose Pablo Leone; Roberto A. Leon-Ferre; Kathryn J. Ruddy

doi:10.2217/bmt-2021-0001

A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer

Siddhartha Yadav, Karthik V. Giridhar, Jose Pablo Leone, Roberto A. Leon-Ferre, Kathryn J. Ruddy

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

Abstract

The majority (more than 90%) of male breast cancers (MaBCs) are estrogen receptor-positive, such that endocrine therapy is the mainstay of MaBC treatment. Endocrine therapy has been associated with improved overall survival in observational studies on MaBC, though large randomized clinical trials have never been completed to confirm this benefit in this population. Tamoxifen is currently the preferred drug for both metastatic and adjuvant treatment of MaBC. Known differences in treatment patterns and hormonal milieu between men and women may warrant a unique approach to the management of toxicities in men. This review provides a detailed discussion of endocrine therapy for MaBC.

Original language	English (US)
Article number	20210001
Journal	Breast Cancer Management
Volume	10
Issue number	3
DOIs	https://doi.org/10.2217/bmt-2021-0001
State	Published - Sep 2021

Keywords

CKD4/6 inhibitor
alpelisib
breast cancer
clinical outcomes
endocrine therapy
estrogen receptor
hormone therapy
male
male breast cancer
palbociclib
survival

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.2217/bmt-2021-0001

Cite this

@article{061a6f7d3f4f4343966cd1e055d77e40,

title = "A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer",

abstract = "The majority (more than 90%) of male breast cancers (MaBCs) are estrogen receptor-positive, such that endocrine therapy is the mainstay of MaBC treatment. Endocrine therapy has been associated with improved overall survival in observational studies on MaBC, though large randomized clinical trials have never been completed to confirm this benefit in this population. Tamoxifen is currently the preferred drug for both metastatic and adjuvant treatment of MaBC. Known differences in treatment patterns and hormonal milieu between men and women may warrant a unique approach to the management of toxicities in men. This review provides a detailed discussion of endocrine therapy for MaBC.",

keywords = "CKD4/6 inhibitor, alpelisib, breast cancer, clinical outcomes, endocrine therapy, estrogen receptor, hormone therapy, male, male breast cancer, palbociclib, survival",

author = "Siddhartha Yadav and Giridhar, {Karthik V.} and Leone, {Jose Pablo} and Leon-Ferre, {Roberto A.} and Ruddy, {Kathryn J.}",

year = "2021",

month = sep,

doi = "10.2217/bmt-2021-0001",

language = "English (US)",

volume = "10",

journal = "Breast Cancer Management",

issn = "1758-1923",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer

AU - Yadav, Siddhartha

AU - Giridhar, Karthik V.

AU - Leone, Jose Pablo

AU - Leon-Ferre, Roberto A.

AU - Ruddy, Kathryn J.

PY - 2021/9

Y1 - 2021/9

N2 - The majority (more than 90%) of male breast cancers (MaBCs) are estrogen receptor-positive, such that endocrine therapy is the mainstay of MaBC treatment. Endocrine therapy has been associated with improved overall survival in observational studies on MaBC, though large randomized clinical trials have never been completed to confirm this benefit in this population. Tamoxifen is currently the preferred drug for both metastatic and adjuvant treatment of MaBC. Known differences in treatment patterns and hormonal milieu between men and women may warrant a unique approach to the management of toxicities in men. This review provides a detailed discussion of endocrine therapy for MaBC.

AB - The majority (more than 90%) of male breast cancers (MaBCs) are estrogen receptor-positive, such that endocrine therapy is the mainstay of MaBC treatment. Endocrine therapy has been associated with improved overall survival in observational studies on MaBC, though large randomized clinical trials have never been completed to confirm this benefit in this population. Tamoxifen is currently the preferred drug for both metastatic and adjuvant treatment of MaBC. Known differences in treatment patterns and hormonal milieu between men and women may warrant a unique approach to the management of toxicities in men. This review provides a detailed discussion of endocrine therapy for MaBC.

KW - CKD4/6 inhibitor

KW - alpelisib

KW - breast cancer

KW - clinical outcomes

KW - endocrine therapy

KW - estrogen receptor

KW - hormone therapy

KW - male

KW - male breast cancer

KW - palbociclib

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85116146013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116146013&partnerID=8YFLogxK

U2 - 10.2217/bmt-2021-0001

DO - 10.2217/bmt-2021-0001

M3 - Review article

AN - SCOPUS:85116146013

SN - 1758-1923

VL - 10

JO - Breast Cancer Management

JF - Breast Cancer Management

IS - 3

M1 - 20210001

ER -

A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this